Aligos Lands $25M Upfront Payment for Hepatitis B Drug in China

Aligos Therapeutics has secured a $25 million upfront payment through an exclusive license agreement to commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection treatment.

The deal represents a significant validation of the company's antiviral candidate in one of the world's largest markets for hepatitis B therapeutics. China accounts for a substantial portion of the global hepatitis B patient population, making regional licensing agreements a key revenue driver for developers of viral hepatitis treatments.

Pevifoscorvir sodium has received Breakthrough Therapy Designation in China, a regulatory classification that typically accelerates the development and review timeline for candidate drugs. The designation suggests Chinese health authorities view the compound as offering potential advantages over existing treatment options for hepatitis B.

The exclusive license structure gives the partner full commercialization rights in Greater China, while Aligos retains the ability to develop and market the therapy in other territories. Terms of the agreement did not specify potential milestone payments or royalty arrangements beyond the upfront cash infusion.

Hepatitis B remains a significant therapeutic category despite decades of treatment options. New agents offering improved efficacy, dosing convenience, or resistance profiles continue to attract licensing interest from both multinational pharmaceutical companies and regional players focused on Asian markets. The Breakthrough Therapy Designation in China suggests pevifoscorvir sodium may differentiate on one or more of these clinical parameters.

Aligos's cash position improves materially with the $25 million payment, providing runway for continued development of its viral hepatitis portfolio and other pipeline candidates. The transaction underscores continued investor appetite for hepatitis B therapies with novel mechanisms of action.